IP Library Granted Patent US 8,598,207
Granted Patent B2
US 8,598,207 · App. 13/477,742 · Granted Dec 3, 2013

Compositions containing opioid antagonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,598,207
App. No.
13/477,742
Granted
Dec 3, 2013
Kind
B2
Abstract

Compositions containing opioid antagonists, particularly alvimopan and its active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits, and methods of making and using same are disclosed. In preferred embodiments, invention provides injectable formulations containing opioid antagonists, particularly alvimopan and its active metabolite, having low solubility that may be readily prepared, are stable during storage, and provide maximum levels of opioid antagonists when administered parenterally, particularly via injection. The results are achieved by a combination of processing techniques and component selection.

Claims (26)

1. A composition comprising:

a. alvimopan or a pharmaceutically-acceptable salt thereof;

b. at least one sugar alcohol bulking agent, wherein said at least one sugar alcohol is mannitol; and

c. a bicarbonate or carbonate base.

2. The composition according to claim 1 , wherein the composition comprises sodium carbonate anhydrous.

3. The composition of claim 1 , wherein the composition is obtained by lyophilizing an aqueous formulation comprising alvimopan or a pharmaceutically acceptable salt thereof, mannitol and a carbonate base selected from sodium carbonate and sodium carbonate anhydrous.

4. The composition of claim 3 , wherein the aqueous formulation has a pH in the range of from about 9 to about 11.

5. The solution of claim 4 , wherein the pH of the aqueous formulation is about 10.5.

6. An injectable pharmaceutical composition prepared by admixing in a pharmaceutically acceptable solvent:

a. alvimopan;

b. mannitol; and

c. a bicarbonate or carbonate base in an amount sufficient to provide a pH to said composition in the range of from about 9 to about 11.

7. The composition of claim 6 , wherein the base is a carbonate base.

8. The composition of claim 7 , wherein the base is sodium carbonate or sodium carbonate anhydrous.

9. The composition of claim 6 , wherein the solvent is an aqueous solvent.

10. The composition of claim 9 , wherein said aqueous solvent is water, isotonic sodium chloride solution, Ringer's solution, dextrose solution or lactated Ringer's solution.

11. A partially or fully dried product, wherein the composition of claim 6 has been dried to remove at least a portion of said solvent.

12. The product of claim 11 that has been lyophilized.

13. A dosage form prepared by:

a. admixing alvimopan, mannitol and a bicarbonate or carbonate base in a pharmaceutically acceptable aqueous solvent to form a solution;

b. adjusting pH of said solution in the range of from about 9 to about 11;

c. lyophilizing said solution to form a partially or fully dried product.

14. The composition of claim 13 , wherein the base is a carbonate base.

15. The composition of claim 14 , wherein the base is sodium carbonate or sodium carbonate anhydrous.

16. The composition of claim 13 , wherein the pH of said solution is adjusted in the range of from about 10 to about 10.5.

17. The composition of claim 16 , wherein the pH of said solution is adjusted to about 10.5.

Assignments (4)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: CALIXA THERAPEUTICS, INC.; ADOLOR CORPORATION; CUBIST PHARMACEUTICALS, INC.
Reel/Frame 036180/0070 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 9, 2015
From: ADOLOR CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 036046/0153 →
SECURITY AGREEMENT Recorded Nov 20, 2012
From: CUBIST PHARMACEUTICALS, INC.; ADOLOR CORPORATION; CALIXA THERAPEUTICS, INC.; CUBIST PHARMACEUTICALS HOLDINGS, INC.; CUBIST PHARMACEUTICALS U.S.
To: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
Reel/Frame 029339/0669 →